Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus

Elliot S. Vesell; Charles E. Chambers; G. Thomas Passananti; Laurence M. Demers; Karl H. Beyer

doi:10.1002/j.1552-4604.1993.tb01958.x

Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus

Elliot S. Vesell, Charles E. Chambers, G. Thomas Passananti, Laurence M. Demers, Karl H. Beyer

Research output: Contribution to journal › Article

10 Scopus citations

Abstract

Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients. 1993 American College of Clinical Pharmacology

Original language	English (US)
Pages (from-to)	823-831
Number of pages	9
Journal	The Journal of Clinical Pharmacology
Volume	33
Issue number	9
DOIs	https://doi.org/10.1002/j.1552-4604.1993.tb01958.x
State	Published - Sep 1993

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/j.1552-4604.1993.tb01958.x

Fingerprint Dive into the research topics of 'Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus'. Together they form a unique fingerprint.

Cite this

Vesell, E. S., Chambers, C. E., Passananti, G. T., Demers, L. M., & Beyer, K. H. (1993). Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus. The Journal of Clinical Pharmacology, 33(9), 823-831. https://doi.org/10.1002/j.1552-4604.1993.tb01958.x

@article{a888f06be08a498b8a76490eec32ce61,

title = "Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus",

abstract = "Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients. 1993 American College of Clinical Pharmacology",

author = "Vesell, {Elliot S.} and Chambers, {Charles E.} and Passananti, {G. Thomas} and Demers, {Laurence M.} and Beyer, {Karl H.}",

year = "1993",

month = sep,

doi = "10.1002/j.1552-4604.1993.tb01958.x",

language = "English (US)",

volume = "33",

pages = "823--831",

journal = "Journal of Clinical Pharmacology",

issn = "0091-2700",

publisher = "SAGE Publications Inc.",

number = "9",

}

Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus. / Vesell, Elliot S.; Chambers, Charles E.; Passananti, G. Thomas; Demers, Laurence M.; Beyer, Karl H.

In: The Journal of Clinical Pharmacology, Vol. 33, No. 9, 09.1993, p. 823-831.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus

AU - Vesell, Elliot S.

AU - Chambers, Charles E.

AU - Passananti, G. Thomas

AU - Demers, Laurence M.

AU - Beyer, Karl H.

PY - 1993/9

Y1 - 1993/9

N2 - Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients. 1993 American College of Clinical Pharmacology

AB - Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients. 1993 American College of Clinical Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0027507732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027507732&partnerID=8YFLogxK

U2 - 10.1002/j.1552-4604.1993.tb01958.x

DO - 10.1002/j.1552-4604.1993.tb01958.x

M3 - Article

C2 - 8227479

AN - SCOPUS:0027507732

VL - 33

SP - 823

EP - 831

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 9

ER -